BriaVax is a gene-modified cell therapy commercialized by BriaCell Therapeutics, with a leading Phase III program in Metastatic Breast Cancer. According to Globaldata, it is involved in 7 clinical trials, of which 2 were completed, 3 are ongoing, 1 is planned, and 1 was terminated. GlobalData uses proprietary data and analytics to provide a complete picture of BriaVax’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for BriaVax is expected to reach an annual total of $97 mn by 2039 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Bria-IMT (BriaVax) is under development for the treatment of advanced metastatic breast cancer, triple-negative breast cancer, HER2+ breast cancer and HER2- breast cancer. The vaccine candidate is administered intradermally. The vaccine candidate is a HER2/neu-positive allogeneic (non-self) breast cancer cell line (SV-BR-1) transfected with the GM-CSF gene to produce the naturally occurring cytokine GM-CSF.
BriaCell Therapeutics Overview
BriaCell Therapeutics is an immuno-oncology biotechnology company that focuses on cancer immunotherapy. The company offers pipeline products such as Bria-IMT and Bria-OTS. Bria-IMT, a whole-cell cancer vaccine that is in Phase I/IIa clinical trials in combination with the immunotherapy development candidates retifanlimab. The company is also developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test that determines the patients’ HLA types. It has operations in the US and Canada. BriaCell Therapeutics is headquartered in West Vancouver, British Columbia, Canada.
The operating loss of the company was US$15.3 million in FY2022, compared to an operating loss of US$7.1 million in FY2021. The net loss of the company was US$26.8 million in FY2022, compared to a net loss of US$13.8 million in FY2021.
For a complete picture of BriaVax’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.